AzTrials
AzTrials

Postoperative HypoparathyroidismPRESSPARNCT07491601

PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"

A study testing Active vitamin D and Calcium in people with Postoperative Hypoparathyroidism and Postsurgical Hypoparathyroidism, run by Nicolas Schlegel at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Active vitamin D and Calcium
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
336 participants
Where
1 siteGermany
Study dates
8 Jan 2025to 31 Dec 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years
  • Thyroidectomy or bilateral thyroid resection of any indication
  • Written informed consent obtained after detailed patient information and provision of an information sheet

Who cannot join

  • Age ≤ 18 years
  • Concomitant parathyroid disease (primary or secondary hyperparathyroidism, pre-existing hypoparathyroidism of any cause)
  • Previous surgery in the neck region
  • Pregnancy or breastfeeding
  • Inability to attend study visits
  • Participation in another study that interferes with the endpoints
  • Missing or inadequate patient information

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nicolas Schlegel, Prof. Dr. (MD) contact

+49 931 201 38217

SCHLEGEL_N@ukw.de

Nicole Kirschbauer, Study Nurse contact

+49 931 201 31173

kirschbauer_n@ukw.de

Germany1 site, 1 recruiting
  • Dept. Surgery I; University Hospital Wuerzburg

    Würzburg, Bavaria, 97080

    Nicole Kirschbauer, Study Nurse, +49 931 201 31173, kirschbauer_n@ukw.de

    Ruth G Gubba, MD, +49 931 201 31176, Gubba_R@ukw.de

    Recruiting

Other trials in Germany

About this study

This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. It will lead to an improvement in quality of life and a reduction in the distress experienced by affected patients. In addition, it is conceivable that patients' hospital stay could be shortened.

Read the detailed description

Information and Recruitment First, patients who meet the inclusion criteria and do not meet any exclusion criteria will be identified in our surgical-endocrine outpatient clinic. All concomitant medications, particularly any pre-existing vitamin D intake, will be documented. As part of the routine blood sampling, parathyroid hormone, calcium, and vitamin D are determined according to the guidelines in order to detect any pre-existing parathyroid disorders (exclusion criteria). After informing the patient about the indication, necessity, and risks of the planned procedure, an additional explanation is given regarding the possibility of participating in the study.

Both written and oral information about the study will be provided to the patient.

Study Timeline The planned recruitment period is 3 years, followed by a 6-month follow-up. Study Visits After patients are enrolled in the study, baseline characteristics are collected, as well as quality-of-life data using standardized questionnaires (SF-36, STAI-G) and the Health Patient Questionnaire (HPQ28), along with a modified version of the "Hypoparathyroidism Patient Experience Scale - Symptom (HPES)." This questionnaire is included in the appendices and has so far been validated for chronic hypoparathyroidism. Validation for the acute setting is currently being carried out through targeted surveys of our own patient cohort during routine perioperative visits.

Postoperative clinical visits take place on days 0, 1, and 2 in accordance with current clinical standards. In the intervention group, parathyroid hormone is measured directly postoperatively within the first 3 hours after surgery. In the control group, this measurement is performed on the first postoperative day (within 24 hours after surgery) during routine blood sampling. This measurement is also carried out at the same time point-on the first postoperative day-in the intervention group. In both groups, vitamin D and calcium supplementation is initiated if the parathyroid hormone level falls below the normal range. On postoperative days 1 and 2, both groups complete the HPES, HPQ28, and STAI-G questionnaires.

As part of the study, an additional clinical visit and laboratory testing is performed after discharge on days 8-10. This additional visit is normally conducted only in patients who showed abnormalities during their hospital stay, such as low calcium or parathyroid hormone levels.

Finally, after 6 months, patients are contacted again by telephone to assess the secondary endpoints, including a renewed evaluation of quality of life. The telephone follow-up also determines whether patients are still experiencing any symptoms at that time and whether continued vitamin D and calcium supplementation is necessary. For patients who did not develop postoperative hypoparathyroidism, the goal is to exclude the possibility that delayed symptoms have occurred (even though this is rare). Furthermore, it should be clarified whether early intervention to prevent symptomatic hypoparathyroidism leads to better long-term quality of life.

Patients in whom the condition persists long-term-i.e., after 6 months-will, as in current clinical routine, be referred to endocrinology for ongoing therapy and monitoring. There is already close collaboration with Prof. Dr. Stefanie Hahner and Prof. Dr. Carmina Fuß in endocrinology. This follow-up is no longer part of the study.

Together with the collaborating partners from endocrinology measurements of parathyroid hormone and calcium levels will be performed according to the UKW standard in the central laboratory and in the endocrinology laboratory. The standards and measurement methods in both laboratories are well established. No technical changes are expected in the coming years, as new devices for parathyroid hormone testing were recently acquired by the endocrinology department.

Randomization Randomization is carried out during or shortly after the surgical procedure by staff of the Surgical Study Center Würzburg. Randomization is performed using the platform "Randomizer.at." Registration takes place after approval by the ethics committee.

Being tested
Active vitamin D, Calcium
Keywords
Thyroid surgery, Perioperative medicine, Postoperative Hypoparathyroidism, Calcium supplementation, Active Vitamin D supplementation, Quality of life after surgery, Post-surgical Hypoparathyroidism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Active vitamin DDrug

    Application if parathyroid hormone level falls below normal

  • CalciumDrug

    Administered if parathyroid hormone level falls below normal

Study groups in NCT07491601
Study groupRoleWhat they receive
Standard of CareSham comparatorMeasurement of parathormone levels and calcium on postoperative day 1 (beginning at day 1 after surgery)
Receives: Drug: Active vitamin D; Drug: Calcium
Early postoperative sampling of parathyroid hormone and Calcium (within 1-3 hours after surgery))ExperimentalMeasurement of parahthyroid hormone and calcium within 1-3 hours post surgery
Receives: Drug: Active vitamin D; Drug: Calcium

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Symptomatic hypoparathyroidism (symptom score) with hypocalcemia

    Symptomatic hypoparathyroidism is defined as the presence of one or more symptoms reported in the questionnaire.

    Measured: within hospital stay (0-48hours after bilateral thyroid surgery)

Secondary outcomes (4)
  1. Length of Hospital stay

    Duration of hospital stay

    Measured: up to 14 days after surgery, on average 2 days

  2. Initation of substitution therapy with active vitamin D and calcium

    Duration of supplementation based on symtptoms and biochemical restoration of PTH levels

    Measured: up to 6 months after surgery

  3. Quality of life with changes in psychological burden

    Measurement of Quality of Life using Short Form (36) Healthy Survey (SF36), State-Trait Anxiety Inventory- German version (STAI-G) and Hypoparathyroidism Patient Questionnaire 28 (HPQ28)

    Measured: up to 1 day before surgery or earlier and after 6 months after surgery

  4. Patient readmission due to hypocalcemia with or without symptoms

    Patients with problems after discharge who require readmission

    Measured: up to 6 months after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2026
  2. Study start8 Jan 2025
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion31 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
This is a multicenter, two-arm, randomized interventional study. It is important to emphasize that patients receive the same diagnostics and treatment as currently standard practice. The only difference is that these are either performed earlier, depending on allocation to one of the study arms, or carried out at the usual time according to current practice.
Masking
None (open label)
Enrolment
336 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07491601
Sponsor's protocol ID
Version II /05- 2024
Acronym
PRESSPAR
Status last verified
Dec 2025
First submitted
5 Dec 2025
Last updated
24 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared due to data protection regulations and lack of participant consent for data sharing

Questions about this trial

What is this clinical trial studying?

A study testing Active vitamin D and Calcium in people with Postoperative Hypoparathyroidism and Postsurgical Hypoparathyroidism, run by Nicolas Schlegel at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nicolas Schlegel, Prof. Dr. (MD) (+49 931 201 38217, SCHLEGEL_N@ukw.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Symptomatic hypoparathyroidism (symptom score) with hypocalcemia (time frame: within hospital stay (0-48hours after bilateral thyroid surgery)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in